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Abstract
Background: Two high-risk genes have been implicated in the development of CM (cutaneous
melanoma). Germline mutations of the CDKN2A gene are found in < 25% of melanoma-prone
families and there are only seven families with mutation of the CDK4 gene reported to date. Beside
those high penetrance genes, certain allelic variants of the MC1R gene modify the risk of developing
the disease.
The aims of our study were: to determine the prevalence of germline CDKN2A mutations and
variants in members of families with familial CM and in patients with multiple primary CM; to search
for possible CDK4 mutations, and to determine the frequency of variations in the MC1R gene.
Methods: From January 2001 until January 2007, 64 individuals were included in the study. The
group included 28 patients and 7 healthy relatives belonging to 25 families, 26 patients with multiple
primary tumors and 3 children with CM. Additionally 54 healthy individuals were included as a
control group. Mutations and variants of the melanoma susceptibility genes were identified by
direct sequencing.
Results: Seven families with CDKN2A mutations were discovered (7/25 or 28.0%). The L94Q
mutation found in one family had not been previously reported in other populations. The D84N
variant, with possible biological impact, was discovered in the case of patient without family history
but with multiple primary CM. Only one mutation carrier was found in the control group. Further
analysis revealed that c.540C>T heterozygous carriers were more common in the group of CM
patients and their healthy relatives (11/64 vs. 2/54). One p14ARF variant was discovered in the
control group and no mutations of the CDK4 gene were found.
Most frequently found variants of the MC1R gene were T314T, V60L, V92M, R151C, R160W and
R163Q with frequencies slightly higher in the group of patients and their relatives than in the group
of controls, but the difference was statistically insignificant.
Conclusion: The present study has shown high prevalence of p16INK4A mutations in Slovenian
population of familial melanoma patients (37%) and an absence of p14ARF or CDK4 mutations.
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Background
Cutaneous melanoma (CM) is the most common cause of
death from skin cancer [1]. According to epidemiology
studies, the risk of CM is influenced by genetic and envi-
ronmental factors. Exposure to UV radiation is the main
environmental factor, while the genetic basis of CM is
complex and appears to involve multiple genes. It is now
widely recognized that autosomal dominant inheritance
of certain genes is associated with predisposition to CM.
Two high penetrance melanoma susceptibility genes,
CDKN2A and CDK4, and a low penetrance gene, MC1R,
have been identified [2].
CDKN2A is a tumor suppressor gene encoding two dis-
tinct proteins from alternatively spliced transcripts [3].
One of those proteins is p16INK4A, which inhibits the
CDK4/6 mediated phosphorilation and inactivation of Rb
(retinoblastoma) protein. The alternative reading-frame
product – p14ARF inhibits the MDM2-mediated ubiquit-
ylation and subsequent degradation of p53 protein [4].
Mutations affecting only the p14ARF protein product are
rare.
Germline CDKN2A mutations have been detected in 10–
25% of melanoma-prone families from North America,
Europe and Australia [5]. Studies in the past have also
indicated an increased risk of pancreatic cancer (PC) in
families with CDKN2A mutations [6].
In contrast to numerous cases of CDKN2A mutations in
families with CM, to our knowledge only seven families
with  CDK4  germ-line mutations have been identified
worldwide [7]. The CDK4 gene is an oncogene encoding
cyclin dependent kinase 4. All reported CDK4 mutations
are located in exon 2, which codes for the p16INK4A
binding site [3].
The gene encoding melanocortin 1 receptor protein
(MC1R) does not play a part in cell cycle regulation. It is
expressed on epidermal melanocytes, functioning as a
binding receptor for alpha melanocyte-stimulating hor-
mone (MSH). MC1R-MSH complex induces cyclic-AMP
tyrosinase activity and melanin production [2]. The MC1R
gene determines the type of melanin produced in the skin,
but its role in melanoma carcinogenesis reaches beyond
its pigmentation effects. MC1R variants R151C, R160W
and D294H are associated with a skin phenotype prone to
the development of CM (red hair, fair skin, freckles and an
inability to tan). These variants are known as RHC (red
hair color) variants and are associated with an increased
risk of developing CM independently of skin phenotype.
It is believed that they also act as modifiers of CM risk in
carriers of CDKN2A mutations [8-10].
Slovenia has a geographical latitude of 46°02' and two
million inhabitants. The reported incidence rate of CM
was 14.5 per 100 000 for males and 14.9 for females in the
time period 2000 to 2004. In the year 2006, the expected
incidence rate was 16 per 100 000 [11].
The major aims of our study were: i) to determine the
prevalence of germline CDKN2A  mutations and varia-
tions in members of families with familial CM and in
patients with multiple primary CM; ii) to search for indi-
viduals/families with possible CDK4  mutations; iii) to
determine the frequency of MC1R gene variants and to
correlate them with development of CM in the population
of patients from melanoma families and their healthy rel-
atives. In an extended genotyping, we also looked for the
same genetic alterations among healthy individuals
belonging to the control group.
Methods
Patients
From January 2001 to January 2007, 64 individuals were
included in this study of melanoma susceptibility genes,
after being referred to the Institute of Oncology Ljubljana
for further treatment or genetic counseling. The group
comprised 28 patients and 7 of their healthy relatives
belonging to 25 melanoma families, and 26 patients with
multiple primary CM. Melanoma families were defined
as: (a) having at least two affected family members, or (b)
a case of PC in a first-degree relative. In two cases family
history was based on a second-degree relative with CM.
All included unaffected members of the melanoma fami-
lies were patient's first degree relatives. Additionally, 3
children diagnosed with CM at eight, nine and twelve
years were included. They were not members of
melanoma families. In all cases the diagnosis of CM was
confirmed by pathology report and family histories were
obtained from personal interviews. Additional cancers
that were reported in this study were colon cancer (three
families), lung cancer (two families) and breast, prostatic
and non-melanoma skin cancer (each in one family). All
adult patients, and the parents of the three children, were
informed about the genetic research protocol and signed
a consent form agreeing to donate blood samples. The
study was reviewed and approved by the Slovenian
National Medical Ethics Committee. Table 1 contains
demographic details about the study population.
Healthy controls
Randomly chosen individuals were invited to donate
blood samples at the Institute of Oncology Ljubljana.
Individuals previously diagnosed with cancer were
excluded. All participants agreed that their blood sample
can be used to create a DNA bank, which could be repeat-
edly used in various genetic researches, but they will not
be informed about the research results. 54 DNA samples
of volunteers with comparable sex and age were chosen
from that bank in order to match the individuals in the
group of patients and their relatives. The group includedBMC Medical Genetics 2008, 9:86 http://www.biomedcentral.com/1471-2350/9/86
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28 females (aged 24 – 70 years) and 26 males (aged 24 –
63). At the time of study, 48.1% of individuals were under
45 years and 51.8% of individuals were older than 45
years.
Mutation screening of melanoma susceptibility genes
For mutation analysis, genomic DNA was isolated from
10 ml of peripheral blood using QIAamp® DNA Blood
Maxi kit (Qiagen, Hilden, D) according to the manufac-
turer's protocol.
Exons 1α, 1β, 2 and 3, including part of promoter region
and 3'-UTR region of the CDKN2A gene, exon 2 of the
CDK4 gene and the coding sequence of the MC1R gene
were amplified by polymerase chain reaction (PCR) as
described previously [12-14].
Direct sequencing, using an automated fluorescence-
based cycle sequencer (ABI Prism® 310 Genetic Analyzer,
Applied Biosystems, Warrington, UK), identified muta-
tions/variants. Chromatograms were read with the aid of
ABI Prism 310 software (Applied Biosystems) and utiliz-
ing the Gene Runner software tool, version 3.05. Number-
ing of variants relates to the following reference
sequences,  CDKN2A  gene: GeneBank accession no.
AF527803 for coding region and 3'-UTR region, and
X94154 for promoter region, CDK4  gene: GeneBank
accession no. AF507942 and MC1R  gene: GeneBank
accession no. AF263461.
Statistics
Pearson Chi-Square test was used to compare the number
of different variant carriers between the patients and the
control group.
Student's t test was used for mean age comparison of
patients who were p16INK4A mutation-positive and
those who were mutation-negative.
Allele frequencies of MC1R variants were defined as the
percentage of times that a given allele is present at a locus
within each tested group and compared with Fisher's exact
test. All statistical analyses were performed with the Statis-
tical Package for Social Sciences (SPSS) v. 15.0. P-values
less than 0.05 were considered statistically significant.
Results
Sequencing of the 1α, 2 and 3 CDKN2A exons revealed 11
different allelic variants presented in Table 2. There were
7 mutations (named p16INK4A mutations), one variant
of the coding region, one variant of 5'UTR and two vari-
ants of 3'UTR. In all but one case, the mutations were dis-
covered in the group of patients with positive family
history or their relatives (14/35). One mutation (D153E)
was found only in the group of healthy control individu-
als. In the same group, we found one case of a A148T var-
iant, which was also found in one case of familial
melanoma and in two cases of multiple primary CM. Alto-
gether three patients with multiple primary CM had two
different allelic variants of the coding region (two cases of
A148T and one of D84N variant, 3/26). Analysis of the
samples taken from the three children revealed no
changes in the coding region of CDKN2A (Table 2), but it
showed that they were all heterozygous for the same
5'UTR and 3'UTR variants. Three out of four families with
≥ 3 cases of CM were mutation-positive (3/4).
In the group of patients and their relatives, 38 individuals
had the -191Met A > G variant of 5'UTR (38/64) com-
pared to 31 cases in the control group (31/54). In both
groups, most of the cases were heterozygous. Sequencing
of 3'UTR gave similar results considering the IVS3+29C >
G (c.500C > G) variant (22/64 vs. 13/54). Comparing
both groups for another allelic variant showed that
IVS3+69C > T (c.540C > T) heterozygous carriers were
more common in the group of patients with CM and their
healthy relatives (11/64 vs. 2/54). Results are presented in
Table 3. There were no differences in the distribution of
variants considering family history or multiple primary
CM.
Sequencing of the exon 1β revealed no mutations in the
group of patients with CM or their healthy relatives. In the
Table 1: Demographic details
Study population (n = 64)
Family history Unaffected relatives Multiple primary CM Child Gender
female male
No 28 7 26 3 41 23
Age at the time of diagnosis (years) of 57 patients*
Pts No (%) < 15 < 45 > 45
3 (5.3%) 25 (43.8%) 29 (50.8%)
Families (n = 25)
< 3 affected members ≥ 3 affected members CM and PC
No of fam. 17 4 4
* the 7 healthy relatives are not includedBMC Medical Genetics 2008, 9:86 http://www.biomedcentral.com/1471-2350/9/86
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control group, we found the F23F allelic variant (num-
bered from the second start codon).
At the time of diagnosis, mean age of patients who were
p16INK4A mutation-positive was 38.40 years compared
to 45.11 years for mutation-negative patients (p = 0.257).
There were no mutations found on exon 2 of the CDK4
gene in our population of CM patients or healthy control
individuals.
Analysis of the complete MC1R sequence revealed 14 dif-
ferent variants, including "R" alleles and 1 deletion (Table
4). The most frequently found ones were T314T, V60L,
V92M, R151C, R160W and R163Q. D294H was among
rarely encountered variants. The deletion was found in the
case of a patient with no family history, but with multiple
primary CM.
There were 11 carriers of at least one MC1R variant in the
group of individuals with one of the CDKN2A  coding
region allelic variants. Three healthy carriers of the
p16INK4A mutation also had at least one MC1R variant,
but in the six p16INK4A mutation carriers with CM, there
were no MC1R variants found (Table 5).
Discussion
We analyzed melanoma susceptibility genes in the DNA
samples of 64 individuals with multiple primary CM and/
or family history of CM. Many of them (35/64 or 54.7%)
had a family history of CM and/or PC and belonged to 25
different melanoma families. In order to avoid mistaking
allelic variants commonly present in Slovenian popula-
tion as variants observed in CM cases, we additionally
analyzed DNA samples of 54 healthy individuals.
Since the mutation carriers belonged to 7 different CM
families, the frequency of mutation-positive families was
7/25 (28.0%). Of 35 individuals with positive family his-
tory 13 (37%) were p16INK4A mutation-positive. This is
similar to northern parts of neighboring Italy (25% of
families with two CM cases), where frequencies vary
according to each specific region [15]. Researchers from
Germany, Poland and Latvia report much lower frequen-
cies or absence of p16INK4A mutations [7,16,17]. In Utah
reported frequency for melanoma families is also lower,
only 8.3% – 10% in physician-referred pedigrees. One
possible reason for the observed high mutation rate in our
population of CM families is that their recruitment was
based on physician referral. Population-based assess-
ments usually report somewhat lower presence of
CDKN2A mutations [1].
The percentage of p16INK4A mutation-positive families
was higher in the case of families with 3 affected mem-
bers, as expected [18]. In our study only 4 families had
three members with CM and three of those families were
Table 2: CDKN2A variants among individuals with family history, patients with multiple primary CM, and healthy controls
POSITIVE CASES
Location CDKN2A  
nucletide
change
Aminoacid 
change
Pts with  
family history
(28)
Healthy
relatives
(7)
Families 
(25)
Pts with multiple
primary only
(26)
Children 
(3)
Healthy
controls
(54)
Exon 1α 68G > A G23D 2 1 2 0 0 0
Exon 1α 71G > C R24P 1 1 1 0 0 0
Exon 1β 69C > T F23F 0 0 0 0 0 1
Exon 2 250G > A D84N 0 0 0 1 0 0
Exon 2 281T > A L94Q 3 2 1 0 0 0
Exon 2 301G > T G101W 2 0 2 0 0 0
Exon 2 442G > A A148T 1 0 1 2 0 1
Exon 2 459C > A D153E 0 0 0 0 0 1
Intron 1 IVS1-1G > A 1 0 1 0 0 0
Table 3: Variants in 5'- and 3'-UTRs
3'UTR and 5'UTR VARIANTS
Positive cases
Location CDKN2A  
nucletide
change
Pts and healthy  
relatives
(n = 35)
Healthy  
controls
(n = 54)
3'-UTR 500C > G 22 13
3'-UTR 540C > T 12 2
5'-UTR -191A > G 38 31
Pts with CM 
(n = 28)
Healthy controls 
(n = 54)
500C > G heterozygous 17 12
homozygous 2 1
540C > T heterozygous 11 2
homozygous 1 0
-191A > G heterozygous 26 28
homozygous 8 3BMC Medical Genetics 2008, 9:86 http://www.biomedcentral.com/1471-2350/9/86
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p16INK4A mutation-positive (75%). In one of the pedi-
grees with three cases of CM, the mutation L94Q was
detected, a mutation that has not previously been
described in other populations [12].
Two families in our study were G101W positive. G101W
is the most common missense mutation identified in
melanoma pedigrees. This type of mutation is known as a
founder mutation in our neighboring country Italy. The
presence of the mutation in Slovenia could be the conse-
quence of genetic material spreading through the geo-
graphical region [19]. In fact, one family did have an
Italian ancestor.
All the mutations discovered in the patient group were
located on exons 1α and 2, there were no mutations
found on exon 1β. Mutations located on exon 1β affecting
only p14ARF are generally rare [20,21]. In our study, the
only allele variant detected on the exon 1β – F23F was
detected in one of the individuals from the control group.
Family history and the presence of mutation are usually
related to an earlier onset of the disease. The p16INK4A
mutation-carriers in our study developed CM earlier than
the patients without mutation, but the difference did not
reach statistical significance (p = 0.257). This could be
explained by the fact that all of the individuals with CM
(both mutation positive and negative) had a family his-
tory of CM or multiple primary CM.
According to the literature, individuals carrying
p16INK4A mutations are at a higher risk for developing a
PC [6]. There were 4 CM/PC families in our study. In one
of these families the variant A148T was detected. This var-
iant was described in previously published studies as a
polymorphism without any deleterious influence on the
p16INK4A protein [22]. One study reported that A148T
heterozygous carriers were more likely to have a first-
degree relative with cancer of any type [23].
There were no deleterious CDKN2A mutations found in
the three children, but all of them were positive for
500C>G and -191MetA>G variants. There were also no
Table 4: Distribution of MC1R variants among patients with CM and their healthy relatives and in the control group.
No MC1R variant Pts and healthy relatives 
(n = 64)
Allel Freq. 
(%)
Control group 
(n = 54)
Allel Freq. 
(%)
p
Protein Nucleotide
1 p. V60L c.178G > T 11 8.6 9 8.3 1.00
2 p. V92M c.274G > A 13 10.1 9 8.3 0.66
3 p. R142H c.425G > A 1 0.8 0 0.0 1.00
4 p.R151C* c.451C > T 12 9.4 6 5.5 0.32
5 p.I155T c.464T > C 1 0.8 0 0.0 1.00
6 p.R160W* c.478C > T 11 8.6 8 7.4 0.81
7 p.R163Q c.488G > A 6 4.7 4 3.7 0.75
8 p.R213W C.637C > T 1 0.8 0 0.0 1.00
9 p.A218T c.652G > A 0 0.0 1 0.9 0.46
10 p.G239G c.717C > T 0 0.0 1 0.9 0.46
11 c.754delC 1 0.8 0 0.0 1.00
12 p.L286V c.856C > G 2 1.6 0 0.0 0.50
13 p.D294H* c.880G > C 1 0.8 0 0.0 1.00
14 p.T314T c.942A > G 14 10.9 10 9.2 0.82
15 p.S316S c.948C > T 0 0.0 1 0.9 0.46
* "R" alleles: RHC variants were classified by strength of association with red hair into strong and weak RHC alleles. Strong alleles included 
p.R151C, p.R160W, p.D294H and were designated as "R".
Table 5: CDKN2A and MC1R allelic variants in patients with CM
CASE CM CDKN2A allel. variants MC1R alleles
1 yes, multiple p.L94Q "R"
2 yes, multiple p.L94Q
3 no p.L94Q "r"
4 yes p.L94Q
5 no p.L94Q "R"
6 yes, multiple p.G23D "r"
7n o p . G 2 3 D " R "
8 yes, multiple IVS1-1g>a "R"
9 yes, multiple p.G101W
10 yes, multiple p.R24P "r"
11 yes p.A148T "R"
12 yes p.G101W
13 yes p.A148T
14 no p.R24P "r"
15 yes p.G23D "r"
16 yes, multiple p.A148T "r"
17 yes, multiple p.D84NBMC Medical Genetics 2008, 9:86 http://www.biomedcentral.com/1471-2350/9/86
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mutations found in the study published by Whiteman, so
the conclusion is that other genes are important in the
genesis of an early-onset melanoma [24].
We included in the study 26 patients with multiple pri-
mary CM without family history of the disease. Multiple
primary CM could alone indicate an underlying genetic
predisposition [15,25]. In the group of p16INK4A muta-
tion carriers, six (6/13) patients indeed developed multi-
ple primary CM. Only one patient without family history
tested positive for possible p16INK4A mutation, in this
case D84N. Many patients with multiple primary tumors
were carriers of at least one of the 5'-UTR or 3'-UTR vari-
ants (18/26). There were also two carriers of the exon 2
allelic variant (A148T) in the group. The remaining eight
patients with multiple primary CM had no changes in the
CDKN2A sequence (8/26).
To the best of our knowledge there are no previous
descriptions of the D84N variant. It is part of the coding
region of the CDKN2A gene and as such may affect the
protein function.
There are numerous reports about the prevalence of 3'UTR
variants in the population of patients with CM, but the
conclusions drawn in these studies are sometimes contra-
dictory [23,26,27].
The prevalence of -191MetA>G did not differ between the
group of CM patients and the control group in our study,
which could confirm previous reports about low signifi-
cance of that allelic variant in development of CM [28].
Although some authors report a higher prevalence of
500C>G in the population of CM patients and possible
influence on the course of the disease, we also found high
prevalence in the group of healthy individuals (19/64 vs.
13/54) [27]. The only observed difference between the
group of healthy individuals and the patients with CM
was the presence of the T allele (or 540C>T heterozygous
carriers, 11/64 vs. 2/54). The heterozygous carriers were
more numerous in the group of patients but after applying
Bonferroni correction to account for multiple tested
groups, the difference was statistically insignificant. A sim-
ilar observation was reported by Kumar in the group of
patients with sporadic CM [26]. In the study performed
on Latvian sporadic CM patients, no changes in the fre-
quency of both 3'UTR allelic variants were observed. The
investigated polymorphic variants could have some influ-
ence on the CM risk by altering the level of CDKN2A tran-
scription or by being in linkage disequilibrium with some
unknown high-risk variant which could be the subject of
further investigations [29].
We did not discover a pedigree with CDK4 mutation in
our population of familial CM, but this was expected since
these mutations are very rare and affected families usually
have numerous cases of CM [5,30].
The search for the MC1R variants led to results that were
in conjunction with recently published reports about
allele frequency across different populations [31]. Inter-
estingly, the most common variant in our population was
T314T with as high a frequency as in French and Dutch
populations. Among all of the studied populations, V92M
was one of the most common variants and this was also
the case in our results, but the frequency was somewhat
higher than that reported for Italian or Greek populations.
V60L proved to have the same frequency as V92M and
similar frequencies as in Dutch and French populations
but higher than in Italian and Greek studies. We discov-
ered rather high frequencies of RHC variants R151C and
R160W, but only one case of D294H. The evaluation of
allele frequencies by Gerstenblith presented significantly
different distribution of MC1R variants across Caucasians.
The allele frequency of combined RHC variants showed a
geographic gradient with decreasing frequency from
North to South with frequencies of 21.5%, 8.5% and
2.9% in Britain/Ireland, Italy and Greece, respectively
[31]. The results from our population rank us somewhere
in between and they probably reflect our geographical
position and intensive migrations in the past. Frequencies
of the most frequent allelic variants were slightly higher in
the group of patients and their relatives than in the group
of controls but the differences did not reach statistical sig-
nificance. Four individuals with p16INK4A mutation had
also one of the "R" alleles. Two of them developed CM but
two are currently healthy. Based on this, no conclusions
can be made about the influence of "R" alleles on
p16INK4A penetrance [9]. The effect of discovered MC1R
variants on the individual's pigmentation characteristics,
or risk of skin cancer, remains to be elucidated.
Conclusion
The present study has shown a high prevalence of
CDKN2A  mutations affecting p16INK4A in Slovenian
population of familial melanoma patients (37%) and an
absence of p14ARF or CDK4 mutations. This indicates the
need to continue with the study of melanoma susceptibil-
ity genes in the Slovenian population in order to design
effective prevention programs.
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